Vinay Prasad returns to FDA as head of CBER

Vinay Prasad is returning to the Food and Drug Administration to lead the Center for Biologics Evaluation and Research. Prasad left the agency less than two weeks ago amid tensions over Sarepta’s (SRPT) Duchenne’s muscular dystrophy gene therapy treatment. Health and Human Services spokesperson Andrew Nixon told media outlets Saturday: “At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research.” Other gene therapy stocks include Capricor Therapeutics (CAPR), Taysha Gene Therapies (TSHA) and MeiraGTx (MGTX).